Details of the Drug Reposition

General Information of This Drug (ID: DMYTJG7)

Drug Name
AG-270   DMYTJG7
Synonyms
REOUTEBTFSILJY-UHFFFAOYSA-N; AG 270; 3(2H)-Pyridazinone, 6-(m-methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-, hydrochloride; 6-(m-Methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-3(2H)-pyridazinone hydrochloride; Morpholinoethyl-2 methyl-4 (m-methoxyphenyl)-6 pyridazone-3 chlorhydrate [French]; 13299-99-5; AC1L496O; DTXSID20157888; Morpholinoethyl-2 methyl-4 (m-methoxyphenyl)-6 pyridazone-3 chlorhydrate; LS-130006; 6-(3-methoxyphenyl)-4-methyl-2-(2-morpholin-4-ylethyl)pyridazin-3-one hydrochloride
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [1]
Lymphoma DISN6V4S 2A80-2A86 Phase 1 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03435250) Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss. U.S. National Institutes of Health.